Skip to main content
Advertisement
Advertisement

INSM

INSM logo

Insmed, Inc.

119.92
USD
Sponsored
-5.38
-4.29%
Sep 15, 16:00 UTC -4
Closed
exchange

After-Market

120.14

+0.22
+0.18%

INSM Earnings Reports

Positive Surprise Ratio

INSM beat 17 of 43 last estimates.

40%

Next Report

Date of Next Report
Oct 28, 2026
Estimate for Q3 26 (Revenue/ EPS)
$514.48M
/
-$0.38
Implied change from Q2 26 (Revenue/ EPS)
+20.92%
/
+533.33%
Implied change from Q3 25 (Revenue/ EPS)
+261.44%
/
-78.29%

Insmed, Inc. earnings per share and revenue

On Aug 06, 2026, INSM reported earnings of -0.06 USD per share (EPS) for Q2 26, beating the estimate of -0.79 USD, resulting in a 92.50% surprise. Revenue reached 425.49 million, compared to an expected 400.69 million, with a 6.19% difference. The market reacted with a +33.86% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of -0.38 USD, with revenue projected to reach 514.48 million USD, implying an increase of 533.33% EPS, and increase of 20.92% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Attovia Therapeutics, Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$2.78
Actual
-$4.88
Surprise
-75.25%
logo
Scribe Therapeutics Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$3.03
Actual
-$2.62
Surprise
+13.59%
logo
enGene Therapeutics Inc. Common Stock
Report Date
Sep 08, 2026 For Q3 26
Estimate
-$0.43
Actual
-$0.47
Surprise
-7.16%
logo
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
logo
Immutep Limited - ADR
Report Date
Sep 01, 2026 For Q4 26
Estimate
$0.00
Actual
-$0.02
Surprise
-2,500.00%
logo
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
For Q2 2026, Insmed, Inc. reported EPS of -$0.06, beating estimates by 92.5%, and revenue of $425.49M, 6.19% above expectations.
The stock price moved up 33.86%, changed from $99.02 before the earnings release to $132.55 the day after.
The next earning report is scheduled for Oct 28, 2026.
Based on 10 analysts, Insmed, Inc. is expected to report EPS of -$0.38 and revenue of $514.48M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement